Jiangsu Hengrui Pharma H Share Listing (1276 HK): Valuation Insights
The proposed AH discount can be argued as either light or attractive. I lean toward the latter and would participate in the H Share listing.
480 Views
Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value
Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...
634 Views
CATL A/H Listing - More like ADR Secondary Listing than an A/H Listing - Performance & Subscription
Contemporary Amperex Technology (CATL) (300750 CH) , one of the world’s largest battery solutions providers, aims to raise around US$4bn in its H...
671 Views
CATL H Share Listing (3750 HK): Valuation Insights
At the maximum offer price, the gross proceeds are US$4.0 billion. Our valuation analysis suggests that the low AH discount can be justified. We...
1k Views
CATL A/H Listing - High Quality, Large Size Make It Unavoidable but Needs a Discount
Contemporary Amperex Technology (CATL) (300750 CH) , one of the world’s largest battery solutions providers, aims to raise around US$4bn in its H...
643 Views